Share

June 15, 2021; 96 (24) Contemporary Issues

A Shortage of Neurologists – We Must Act Now

A Report From the AAN 2019 Transforming Leaders Program

Jennifer J. Majersik, Aiesha Ahmed, I-Hweii A. Chen, Holly Shill, Gregory P. Hanes, Victoria S. Pelak, Jennifer L. Hopp, Antonio Omuro, Benzi Kluger, Thabele Leslie-Mazwi
First published April 30, 2021, DOI: https://doi.org/10.1212/WNL.0000000000012111
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
372

Share

Article Information

vol. 96 no. 24 1122-1134
DOI: 
https://doi.org/10.1212/WNL.0000000000012111
PubMed: 
33931527
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received August 10, 2020
  • Accepted in final form March 4, 2021
  • First Published April 30, 2021.

Article Versions

Copyright & Usage: 
© 2021 American Academy of Neurology

Author Disclosures

    1. Jennifer J. Majersik, MD, MS,
    2. Aiesha Ahmed, MD, MBA,
    3. I-Hweii A. Chen, MD, PhD,
    4. Holly Shill, MD,
    5. Gregory P. Hanes, MD,
    6. Victoria S. Pelak, MD,
    7. Jennifer L. Hopp, MD,
    8. Antonio Omuro, MD,
    9. Benzi Kluger, MD, MS and
    10. Thabele Leslie-Mazwi, MD
  1. Jennifer J. Majersik, MD, MS,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Neurology, Editorial Board Member, 2015-present (2) Stroke, Associate Editor, 2020-present (3) UpToDate, Reviewer, 2018-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Commercial entity, Foldax, Inc (2019-20)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH/NINDS, 1U24NS107228 - UT StrokeNet, Principal Investigator, 2018-23 (2) NIH/NINDS, 1U24NS107156 - UR NEXT, Mentor, 2018-23 (3) NIH/NICHD, 1R03HD091432 - Co-Investigator, 2017-19

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Aiesha Ahmed, MD, MBA,
    3. Scientific Advisory Boards:

    1. Genzyme

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. AAN

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Biogen

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. I-Hweii A. Chen, MD, PhD,
    4. Scientific Advisory Boards:

    1. served on Biogen ad-hoc advisory board (2019)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. receive research funding support from NEALS (2019-2020) and UCB (2019)

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Holly Shill, MD,
    5. Scientific Advisory Boards:

    1. US World Meds

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Mitsubishi Tanabe Pharma America, Acadia Pharmaceuticals, Biogen, Kyowa Kirin, Jazz Pharmaceuticals, Acorda Therapeutics

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr. Shill has research support from Impax Laboratories, US World Meds, Sunovion, Biogen, Intec Pharma, Cala Health

    Research Support, Government Entities:

    1. NINDS/NIH. NN110: A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson’s Disease. Oct. 2020- present. Role: Local PI. NINDS/NIH. Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). 9/2018-present. Role: Co-PI. 10% FTE. 1U01NS090259-01A1. NIH/Parkinson Study Group. A randomized, double-blind, placebo-controlled trial of urate-elevating inosine treatment to slow clinical decline in early Parkinson’s disease. SURE-PD. 10/2016- 12/2019. Role: Local PI. 1% FTE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Michael J Fox Foundation for Parkinson Research Barrow Neurological Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Gregory P. Hanes, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1. AbbVie, Inc., honoraria for speaking engagement 2. Catalyst Pharmaceuticals, Inc., honoraria for speaking engagement 3. Allergan PLC, honoraria for speaking engagement

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1. Allergan, PLC 2. AbbVie, Inc. 3. Maglio, Christoher, and Toale, PA

    Speakers' Bureaus:

    1. 1. Allergan, PLC. 2. AbbVie, Inc. 3. Catalyst Pharmaceuticals, Inc.

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1. Allergan, PLC. 2. AbbVie, Inc.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Victoria S. Pelak, MD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 1. Frontiers Neurology: Dementia, (Review Editor), (2018- 2019) 2. Neuro-ophthalmology Virtual Education Library, (Editorial Board), (2018-Present) 3. NOVEL Neuro-ophthalmology Examination Techniques, (Section Editor), (2018-present) 4. Frontiers Neurology: Neuro-ophthalmology (Associate Editor), (2018-Present) 5. Journal of Neuro-ophthalmology, (Editorial Board), (2019-Present) 6. Scientific Reports: Nature, (Editorial Board), (2020- Present) 7. Brain & Life Magazine, (Editorial Board), (2020- Present) 8. StatPearls, (Editor-in-Chief Behavioral Neurology and Neuropsychiatry Section), (2020-Present)

    Patents:

    1. NONE

    Publishing Royalties:

    1. UpToDate, Inc, Royalties for Articles recvd semi-annually for these publications in UpToDate. 1. Pelak VS, Quan D. Ocular Myasthenia Gravis. In: UpToDate, Rose, BD (Ed), UpToDate, Wellesley, MA. 2006. 2. Pelak VS. Visual Hallucinations I and II. In: UpToDate, Rose, BD (Ed), UpToDate, Wellesley, MA, 2009. 3. Pelak VS. Release Visual Hallucinations (Charles Bonnet Syndrome). In: UpToDate, Rose, BD (Ed), UpToDate, Wellesley, MA, 2009.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH, 1R01AG058772-01A1, Co-Investigator, 5 years, NIA

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1. North American Neuro-ophthalmology Society 2. Alzheimer's Association 3. Visual Snow Initiative

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. 1) expert witness testimony and deposition - private lawyers 2) treating physician deposition - private lawyers 3) expert for National Vaccine Injury Compensation Program, Health and Human Services, Health Resources & Services Administration

  7. Jennifer L. Hopp, MD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. (1) Driving restrictions for patients with seizures and epilepsy, UpToDate electronic medical journal, 2007- present

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NINDS 1 UO1 NS08803401, Established Status Epilepticus Treatment Trial (ESETT), Site-PI, Co- Investigator, 2015-2020 (2) 1 U10 NS058932-01 NIH NINDS Neurological Emergencies Treatment Trials (NETT) Network Clinical/Site Hub, PI Maryland Consortium NETT Network Hub, 2017-2020 (3) MII TA Grant 20180828 TEDCO, EpiWatch: A Mobile Health Application for Epilepsy Management, Role: Site PI, Co-Investigator, 2018-present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. (1)GEROLAMO McNULTY DIVIS & LEWBART, A PROFESSIONAL CORPORATION ATTORNEYS AT LAW, Expert witness testimony, 2019-present (2) GOODELL, DEVRIES, LEECH & DANN, LLP, Expert witness testimony, 2020-present

  8. Antonio Omuro, MD,
    9. Scientific Advisory Boards:

    1. (1) Ono (2) Merck (3) Kiyatec

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Current Opinion in Neurology, associate editor for Neoplasm edition, 2019

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH, 5P30CA016359-40, Chair, protocol review committee

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Benzi Kluger, MD, MS and
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1) Davis Phinney Foundation - Speaker Honoraria 2) Parkinson's Association of the Rockies - Speaker Honoraria 3) Movement Disorders Society - Speaker Honoraria

    Editorial Boards:

    1. 1) Frontiers in Movement Disorders, Editorial Board 2) Annals of Palliative Medicine, Editorial Board 3) Palliative Medicine Reports, Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1) National Institutes of Health/NIA, PI, NIH, K02AG062745, 2020-2025 K02 NS080885-01A1 2) NIH/NINR, PI, R01NR016037, 2016-2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1) Patient Centered Outcomes Research Institute

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Thabele Leslie-Mazwi, MD
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology, Division of Vascular Neurology (J.J.M.), University of Utah, Salt Lake City; Departments of Neurology and Medicine (A.A.), Penn State Health, Hershey, PA; Department of Neurology, Division of Neuromuscular Medicine (I-H.A.C.), Medical University of South Carolina, Charleston; Barrow Neurological Institute (H.S.), University of Arizona College of Medicine–Phoenix; Sarasota Memorial Hospital (G.P.H.), FL; Departments of Neurology and Ophthalmology (V.S.P.), University of Colorado School of Medicine, Aurora; Department of Neurology (J.L.H.), University of Maryland School of Medicine, Baltimore; Department of Neurology (A.O.), Yale School of Medicine, New Haven, CT; Departments of Neurology and Medicine (B.K.), University of Rochester Medical Center, NY; and Departments of Neurosurgery and Neurology (T.L.-M.), Massachusetts General Hospital, Boston.
  1. Correspondence
    Dr. Majersik jennifer.majersik{at}hsc.utah.edu
View Full Text

Article usage

Article usage: April 2021 to September 2021

AbstractFullPdfSource
Apr 20218101Highwire
May 2021531036Highwire
Jun 2021159812793Highwire
Jul 20213964147Highwire
Aug 20214772798Highwire
Sep 20214193297Highwire

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me